CRVO
CervoMed Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$37.31M
P/E Ratio
—
EPS
$-2.98
Beta
-5.04
52W High
$11.79
52W Low
$3.51
50-Day MA
$4.55
200-Day MA
$7.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $4.01M |
| Gross Profit (TTM) | $-17.81M |
| EBITDA | — |
| Operating Margin | -95479.00% |
| Return on Equity | -93.90% |
| Return on Assets | -53.60% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $1.97 |
| Price-to-Book | 2.02 |
| Price-to-Sales (TTM) | 9.31 |
| EV/Revenue | 307.67 |
| EV/EBITDA | 1.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $9.26M |
| Float | $5.50M |
| % Insiders | 32.15% |
| % Institutions | 15.54% |
Historical Volatility
HV 10-Day
73.35%
HV 20-Day
70.67%
HV 30-Day
79.26%
HV 60-Day
85.22%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($22.14 target)
8
BuyData last updated: 4/10/2026